Express Script's Chief Drug Procurement Officer to Deliver Keynote at CBI's 7th Annual Bio/Pharma Trade and Channel Strategies E

BOSTON, Oct. 18, 2011 /PRNewswire/ -- Allen Dunehew, Chief Drug Procurement Officer, Express Scripts, will present the keynote address at CBI's 7th Annual Bio/Pharma Trade and Channel Strategies on December 6-7, 2011 in Philadelphia. Dunehew will discuss industry trends and the impact of the PBM at the "Evolution of the PBM/Manufacturing Channel Relationship and Innovations in Supply and Distribution of Brands, Generics and Specialty Rx" session.

Over the years, Trade and Channel Strategies has become the meeting to attend for more than 1,000 life science suppliers and allied healthcare trading partners who convene to discuss next-generation agreements, distribution services, and innovative channel programs.

This year's event features an in-conference Specialty/Retail Channel Strategy Summit that examines new approaches and patient-centered opportunities through the specialty and retail channel. Eighteen speakers round out the event with extended industry panel discussions and a Wall Street address. Networking opportunities are available both days with such industry leaders as Genzyme, Ortho-McNeil, Sunovion Pharmaceuticals, Millennium Laboratories, CVS Caremark, Eli Lilly, GlaxoSmithKline, Bristol Myers Squibb, Johnson & Johnson, Covidien, and more.

For more information about the conference visit  

Contact: Cathy Rossi-Cecere
Phone number: 339-298-2128
Email address: [email protected]

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at


Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.